Search Page

1

Cite

Share

Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers: A randomized phase 2 trial.

Kazierad DJ, Chidsey K, Somayaji VR, Bergman AJ, Birnbaum MJ, Calle RA. Kazierad DJ, et al. Med (N Y). 2021 Jul 9;2(7):800-813.e3. doi: 10.1016/j.medj.2021.04.007. Epub 2021 Apr 27. Med (N Y). 2021. PMID: 35590219 Free article. Clinical Trial.

Cite

Share

2

Cite

Share

Homocysteine as a risk factor for atherosclerosis.

Temple ME, Luzier AB, Kazierad DJ. Temple ME, et al. Among authors: kazierad dj. Ann Pharmacother. 2000 Jan;34(1):57-65. doi: 10.1345/aph.18457. Ann Pharmacother. 2000. PMID: 10669187 Review.

Cite

Share

3

Cite

Share

A review of eprosartan pharmacokinetic and pharmacodynamic drug interaction studies.

Blum RA, Kazierad DJ, Tenero DM. Blum RA, et al. Among authors: kazierad dj. Pharmacotherapy. 1999 Apr;19(4 Pt 2):79S-85S. doi: 10.1592/phco.19.7.79s.30948. Pharmacotherapy. 1999. PMID: 10213526 Review.

Cite

Share

4

Cite

Share

Dilevalol: an overview of its clinical pharmacology and therapeutic use in hypertension.

Lalonde RL, Tenero DM, Kazierad DJ. Lalonde RL, et al. Among authors: kazierad dj. Pharmacotherapy. 1990;10(1):15-28. Pharmacotherapy. 1990. PMID: 2179899 Review.

Cite

Share

5

Cite

Share

Metabolism and excretion of (S)-6-(3-cyclopentyl-2-(4-trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid (PF-04991532), a hepatoselective glucokinase activator, in humans: confirmation of the MIST potential noted in first-in-Human metabolite scouting studies.

Sharma R, Bergman A, Litchfield J, Atkinson K, Kazierad DJ, Kalgutkar AS. Sharma R, et al. Among authors: kazierad dj. Xenobiotica. 2019 Dec;49(12):1447-1457. doi: 10.1080/00498254.2019.1581960. Epub 2019 Mar 7. Xenobiotica. 2019. PMID: 30747552 Clinical Trial.

Cite

Share

6

Cite

Share

Effect of Hepatic Organic Anion-Transporting Polypeptide 1B Inhibition and Chronic Kidney Disease on the Pharmacokinetics of a Liver-Targeted Glucokinase Activator: A Model-Based Evaluation.

Bergman A, Bi YA, Mathialagan S, Litchfield J, Kazierad DJ, Pfefferkorn JA, Varma MVS. Bergman A, et al. Among authors: kazierad dj. Clin Pharmacol Ther. 2019 Oct;106(4):792-802. doi: 10.1002/cpt.1419. Epub 2019 Apr 8. Clin Pharmacol Ther. 2019. PMID: 30919935

Cite

Share

7

Cite

Share

Efficacy and safety of the glucagon receptor antagonist PF-06291874: A 12-week, randomized, dose-response study in patients with type 2 diabetes mellitus on background metformin therapy.

Kazierad DJ, Chidsey K, Somayaji VR, Bergman AJ, Calle RA. Kazierad DJ, et al. Diabetes Obes Metab. 2018 Nov;20(11):2608-2616. doi: 10.1111/dom.13440. Epub 2018 Jul 30. Diabetes Obes Metab. 2018. PMID: 29923286 Clinical Trial.

Cite

Share

8

Cite

Share

Effects of multiple ascending doses of the glucagon receptor antagonist PF-06291874 in patients with type 2 diabetes mellitus.

Kazierad DJ, Bergman A, Tan B, Erion DM, Somayaji V, Lee DS, Rolph T. Kazierad DJ, et al. Diabetes Obes Metab. 2016 Aug;18(8):795-802. doi: 10.1111/dom.12672. Epub 2016 May 12. Diabetes Obes Metab. 2016. PMID: 27059951 Clinical Trial.

Cite

Share

9

Cite

Share

A 4-week study assessing the pharmacokinetics, pharmacodynamics, safety, and tolerability of the glucagon receptor antagonist PF-06291874 administered as monotherapy in subjects with type 2 diabetes mellitus.

Bergman A, Tan B, Somayaji VR, Calle RA, Kazierad DJ. Bergman A, et al. Among authors: kazierad dj. Diabetes Res Clin Pract. 2017 Apr;126:95-104. doi: 10.1016/j.diabres.2017.01.019. Epub 2017 Feb 3. Diabetes Res Clin Pract. 2017. PMID: 28237861 Clinical Trial.

Cite

Share

10

Cite

Share

Man versus machine: is there an optimal method for QT measurements in thorough QT studies?

Darpo B, Agin M, Kazierad DJ, Layton G, Muirhead G, Gray P, Jorkasky DK. Darpo B, et al. Among authors: kazierad dj. J Clin Pharmacol. 2006 Jun;46(6):598-612. doi: 10.1177/0091270006286900. J Clin Pharmacol. 2006. PMID: 16707406 Clinical Trial.

Cite

Share